Nisa Investment Advisors
DAWN

Nisa Investment Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Nisa Investment Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-234
Closed -$5.02K – 3117
2026
Q1 		$5.02K Buy
234
+177
+311% +$2.49K ﹤0.01% 2454
2025
Q4 		$531 Sell
57
-1,000
-95% -$8.35K ﹤0.01% 2805
2025
Q3 		$7.45K Buy
1,057
+11
+1% +$76 ﹤0.01% 2360
2025
Q2 		$6.8K Buy
1,046
+46
+5% +$316 ﹤0.01% 2391
2025
Q1 		$7.93K Sell
1,000
-52
-5% -$560 ﹤0.01% 2156
2024
Q4 		$13.3K Sell
1,052
-42
-4% -$584 ﹤0.01% 2059
2024
Q3 		$15.2K Sell
1,094
-63
-5% -$899 ﹤0.01% 1992
2024
Q2 		$15.9K Buy
1,157
+1,063
+1,131% +$15.6K ﹤0.01% 2019
2024
Q1 		$1.55K Buy
94
+69
+276% +$1.03K ﹤0.01% 2281
2023
Q4 		$365 Sell
25
-762
-97% -$9.24K ﹤0.01% 2468
2023
Q3 		$9.66K Buy
787
+741
+1,611% +$9.67K ﹤0.01% 2183
2023
Q2 		$549 Buy
46
+16
+53% +$209 ﹤0.01% 2540
2023
Q1 		$0 Hold
30
– – ﹤0.01% 2566
2022
Q4 		$1K Buy
+30
New +$615 ﹤0.01% 2417

Other funds holding DAWN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Nisa Investment Advisors's DAWN Position: Q2 2026 in Review

Nisa Investment Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 234 shares — an estimated $5.02K sold.

Nisa Investment Advisors first reported a position in DAWN in Q4 2022 and held it in 14 quarters. The position peaked at $15.9K in Q2 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

  • Nisa Investment Advisors reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Nisa Investment Advisors sold 234 Day One Biopharmaceuticals shares in Q2 2026, an estimated $5.02K.
  • Nisa Investment Advisors first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 14 quarters.
  • Nisa Investment Advisors's Day One Biopharmaceuticals position peaked at $15.9K in Q2 2024.
  • 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.